Phase I
A look at the lucky drugs that have been hailed a breakthrough by the FDA.
GlycoMimetics defied a hematology biotech pitfall Tuesday, breaking out on strong cancer-drug data as shares of Global Blood Therapeutics and Spark Therapeutics trended in the opposite direction.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
The success has prompted Roche to exercise its option to license the product, called IONIS-HTT(Rx), at a cost of $45 million.
The company is shuttering the program and focusing on other compounds in its pipeline after CRS-207 failed in studies.
Celgene and bluebird bio released updated data from an ongoing Phase I clinical trial of bb2121 at the ASH Annual Meeting.
With Sage’s positive data, we may be embarking on a neuroscience renaissance.
Spark Therapeutics, with its partner Pfizer, published interim data from its Phase I/II clinical trial of a gene therapy for hemophilia B in The New England Journal of Medicine.
Nobody is interested in slow-growth or no-growth stocks, long term or short term, but everyone’s interested in fast-growing stocks.
With the $63.5B takeover of Monsanto by Bayer taking longer than expected, and a key patent for Xarelto expiring in 2024, Bayer’s execs are finding themselves defending their decisions.
PRESS RELEASES